Spots Global Cancer Trial Database for anastrozole
Every month we try and update this database with for anastrozole cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer | NCT00075764 | Breast Cancer | anastrozole fulvestrant | 18 Years - | SWOG Cancer Research Network | |
| A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS) | NCT01824836 | Estrogen Recept... Musculoskeletal... Progesterone Re... Recurrent Breas... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | anastrozole questionnaire a... laboratory biom... pharmacogenomic... | 18 Years - | Eastern Cooperative Oncology Group | |
| Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole | NCT00077168 | Breast Cancer | anastrozole tamoxifen citra... adjuvant therap... radiation thera... | 40 Years - 70 Years | National Cancer Institute (NCI) | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) | NCT04964934 | ER-Positive HER... | AZD9833 AZD9833 Placebo Anastrozole Anastrozole pla... Letrozole Letrozole place... Palbociclib Abemaciclib Luteinizing hor... Ribociclib | 18 Years - 130 Years | AstraZeneca | |
| Fulvestrant With or Without Lapatinib and/or Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer That Progressed After Previous Aromatase Inhibitor Therapy | NCT00688194 | Breast Cancer | anastrozole exemestane fulvestrant lapatinib ditos... letrozole placebo | 18 Years - | National Cancer Institute (NCI) | |
| A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease | NCT04711252 | ER-Positive HER... | AZD9833 Anastrozole Anastrozole pla... AZD9833 placebo Palbociclib Luteinizing hor... | 18 Years - 130 Years | AstraZeneca | |
| Liver Safety Under Upfront Arimidex vs Tamoxifen | NCT00537771 | Breast Cancer | Anastrozole Tamoxifen | - | AstraZeneca | |
| PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | NCT01723774 | Breast Neoplasm... | PD0332991 Anastrozole Goserelin Surgery (standa... Tumor biopsy | 18 Years - | Washington University School of Medicine | |
| Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study. | NCT04852081 | Breast Cancer S... | Palbociclib Ribociclib Abemaciclib Letrozole Anastrozole Tamoxifen Fulvestrant Exemestane Alpelisib | 18 Years - | Blokhin's Russian Cancer Research Center | |
| Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer | NCT00437359 | Breast Neoplasm... | Toremifene citr... Anastrozole | - | Japan Breast Cancer Research Network | |
| Pre-Operative Window of Adjuvant Endocrine Therapy to Inform RT Decisions in Older Women With Early-Stage Breast Cancer | NCT04272801 | Breast Cancer F... | tamoxifen, letr... Patient reporte... | 65 Years - | University of Virginia | |
| Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | NCT00077025 | Breast Cancer | Gefitinib Anastrozole | 18 Years - | AstraZeneca | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| Bioequivalency Study of Anastrozole 1 mg Under Fasted Conditions | NCT01155102 | Breast Cancer | Anastrozole | 18 Years - 45 Years | West-Ward Pharmaceutical | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | NCT02947685 | HER-2 Positive ... Estrogen Recept... | palbociclib trastuzumab pertuzumab letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | Alliance Foundation Trials, LLC. | |
| To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy | NCT02549430 | Breast Cancer | Palbociclib Anastrozole Letrozole Exemestane Fulvestrant | 18 Years - | Fondazione Sandro Pitigliani | |
| A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer | NCT00274469 | Metastatic Brea... | fulvestrant anastrozole | 45 Years - 100 Years | AstraZeneca | |
| Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole | NCT00077168 | Breast Cancer | anastrozole tamoxifen citra... adjuvant therap... radiation thera... | 40 Years - 70 Years | National Cancer Institute (NCI) | |
| Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer | NCT00562458 | Advanced Breast... | anastrozole | - | AstraZeneca | |
| Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | NCT00005908 | Breast Cancer Breast Neoplasm | Docetaxel - Dos... Anastrozole cyclophosphamid... Docetaxel - Dos... Doxorubicin hyd... Tamoxifen Citra... Capecitabine - ... Capecitabine - ... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Bicalutamide Plus Aromatase Inhibitors in ER(+)/AR(+)/HER2(-) Metastatic Breast Cancer | NCT02910050 | Breast Cancer | Bicalutamide Aromatase Inhib... | 18 Years - 80 Years | Sun Yat-sen University | |
| A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer | NCT00544986 | Breast Cancer | Anastrozole | 18 Years - | AstraZeneca | |
| Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer | NCT00066378 | Breast Cancer | anastrozole gefitinib | - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer | NCT00077025 | Breast Cancer | Gefitinib Anastrozole | 18 Years - | AstraZeneca | |
| A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients With ER-positive/HER2-negative Early Breast Cancer | NCT05896566 | Breast Cancer | Giredestrant Triptorelin Anastrozole | 18 Years - | ETOP IBCSG Partners Foundation | |
| Arimidex Therapy Compliance Electronic Monitoring System | NCT00936442 | Breast Cancer | Anastrozole Educational mat... | - | AstraZeneca | |
| Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | NCT03220178 | Breast Neoplasm | Palbociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Palleos Healthcare GmbH | |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | NCT06016738 | Breast Cancer Advanced Breast... Metastatic Brea... ER Positive Bre... HER2 Negative B... | Palazestrant Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Olema Pharmaceuticals, Inc. | |
| Impact of Neoadjuvant Hormonal Therapy on the Surgical Management of Extensive Ductal Carcinomas in Situ | NCT04666961 | Ductal Carcinom... Extensive Disea... Mastectomy | Tamoxifen 20 mg Anastrozole 1Mg... | 40 Years - | Institut Cancerologie de l'Ouest | |
| Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery | NCT00398489 | Breast Cancer | trastuzumab anastrozole cyclophosphamid... docetaxel epirubicin hydr... goserelin aceta... tamoxifen citra... adjuvant therap... conventional su... neoadjuvant the... radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not | NCT01553903 | Breast Cancer | Tamoxifen, Exemestane Anastrozole Letrozole | 18 Years - | Institut Claudius Regaud | |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | NCT05467891 | Locoregional Re... Hormone Recepto... HER2-negative B... | Ribociclib Fulvestrant Anastrozole Letrozole Exemestane | 18 Years - | Hoosier Cancer Research Network | |
| Iressa (ZD1839) Plus Anastrozole (Arimidex) in Patients With Ovarian Cancer | NCT00181688 | Ovarian Cancer Peritoneal Carc... Tubal Carcinoma | Iressa (ZD1839) Arimidex (Anast... | 18 Years - | Massachusetts General Hospital | |
| Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC | NCT02140437 | Carcinoma Breas... | Fulvestrant Anastrozole | 18 Years - 80 Years | Fudan University | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer | NCT06361940 | Breast Cancer | Aromatase inhib... | 18 Years - | Medical College of Wisconsin | |
| Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00687648 | Breast Cancer | anastrozole cyclophosphamid... exemestane letrozole methotrexate prednisolone | 18 Years - | National Cancer Institute (NCI) | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | NCT01674140 | Breast Cancer | anastrozole everolimus exemestane goserelin aceta... letrozole leuprolide acet... tamoxifen citra... placebo | 18 Years - | SWOG Cancer Research Network | |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | NCT01368263 | Estrogen Recept... HER2-negative B... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | goserelin aceta... letrozole anastrozole chemotherapy Surgery | 18 Years - | Washington University School of Medicine | |
| Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00217399 | Recurrent Breas... Stage IV Breast... | sorafenib tosyl... anastrozole | 18 Years - | National Cancer Institute (NCI) | |
| Second Line Breast Cancer Trial | NCT00635713 | Advanced Breast... | Fulvestrant Anastrozole Fulvestrant | 18 Years - | AstraZeneca | |
| Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00253422 | Breast Cancer | anastrozole exemestane fulvestrant | - | National Cancer Institute (NCI) | |
| Phase II Study of Everolimus Beyond Progression | NCT02269670 | Estrogen Recept... HER2-negative B... Progesterone Re... Recurrent Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Stage IV Breast... | everolimus anastrozole letrozole tamoxifen citra... fulvestrant megestrol aceta... | 19 Years - | Emory University | |
| Exemestane Versus Anastrozole as First Line Hormone Therapy in Postmenopausal Metastatic Breast Cancer Patients | NCT00128843 | Breast Cancer | Exemestane Anastrozole | 18 Years - 90 Years | Spanish Breast Cancer Research Group | |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer) | NCT04436744 | Early Breast Ca... | Giredestrant Anastrozole Palbociclib Surgery | 18 Years - | Hoffmann-La Roche | |
| Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer | NCT00871858 | Breast Cancer | anastrozole fulvestrant | 18 Years - 100 Years | Institut Bergonié | |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | NCT01368263 | Estrogen Recept... HER2-negative B... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | goserelin aceta... letrozole anastrozole chemotherapy Surgery | 18 Years - | Washington University School of Medicine | |
| Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy | NCT00053898 | Breast Cancer | anastrozole tamoxifen citra... Radiation Thera... | - | NSABP Foundation Inc | |
| Breast Cancer Tumor Care Observational Programme | NCT00660244 | Post Menopausal Arthralgia | anastrozole | - | AstraZeneca | |
| Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer | NCT00588003 | Breast Cancer | anastrozole Placebo | 45 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | NCT00004906 | Breast Cancer | filgrastim anastrozole carboplatin cisplatin cyclophosphamid... docetaxel doxorubicin hyd... etoposide pamidronate dis... thiotepa peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | NCT02057133 | Breast Neoplasm... | LY2835219 Letrozole Anastrozole Tamoxifen Exemestane Everolimus Trastuzumab LY3023414 Fulvestrant Pertuzumab Loperamide Endocrine thera... | 18 Years - | Eli Lilly and Company | |
| Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | NCT00265759 | Breast Cancer | anastrozole exemestane letrozole Therapeutic Con... | - | Alliance for Clinical Trials in Oncology | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| ATAC - Bone Density Sub-Protocol | NCT00784940 | Bone Density | Anastrozole Tamoxifen | 45 Years - | AstraZeneca | |
| Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer | NCT00253422 | Breast Cancer | anastrozole exemestane fulvestrant | - | National Cancer Institute (NCI) | |
| S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | NCT01674140 | Breast Cancer | anastrozole everolimus exemestane goserelin aceta... letrozole leuprolide acet... tamoxifen citra... placebo | 18 Years - | SWOG Cancer Research Network | |
| Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer | NCT00687648 | Breast Cancer | anastrozole cyclophosphamid... exemestane letrozole methotrexate prednisolone | 18 Years - | National Cancer Institute (NCI) | |
| ETHAN - ET for Male BC | NCT05501704 | Male Breast Can... Hormone Recepto... Hormone Recepto... | Tamoxifen Anastrozole Degarelix Abemaciclib | 18 Years - | Dana-Farber Cancer Institute | |
| Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ | NCT00072462 | Breast Cancer | tamoxifen citra... Anastrozole | 40 Years - 70 Years | Queen Mary University of London | |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer | NCT00004906 | Breast Cancer | filgrastim anastrozole carboplatin cisplatin cyclophosphamid... docetaxel doxorubicin hyd... etoposide pamidronate dis... thiotepa peripheral bloo... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | NCT06179303 | Anatomic Stage ... Anatomic Stage ... Locally Advance... Locally Advance... Metastatic HER2... Metastatic Horm... | Abemaciclib Anastrozole Biospecimen Col... Computed Tomogr... Diagnostic Imag... Exemestane Fludeoxyglucose... Fluorine F 18 F... Fulvestrant Gonadotropin-re... Letrozole Positron Emissi... Tamoxifen Therapeutic Est... | 18 Years - | University of Washington | |
| ER Reactivation Therapy for Breast Cancer | NCT02188745 | Metastatic Brea... | 17B-estradiol Letrozole Anastrozole Exemestane | 18 Years - | Dartmouth-Hitchcock Medical Center | |
| Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | NCT03304080 | Breast Neoplasm... Breast Diseases | Anastrozole Palbociclib Trastuzumab Pertuzumab | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer | NCT00217659 | Breast Cancer | anastrozole goserelin aceta... | 18 Years - | SWOG Cancer Research Network | |
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646 | Breast Cancer | tamoxifen anastrozole zoledronic acid goserelin | 19 Years - 59 Years | Austrian Breast & Colorectal Cancer Study Group | |
| Endocrine Response in Women With Invasive Lobular Breast Cancer | NCT02206984 | Breast Cancer | Tamoxifen Anastrozole Fulvestrant | - | University of Pittsburgh | |
| Bioequivalency Study of Anastrozole 1 mg Under Fed Conditions | NCT01155089 | Breast Cancer | Anastrozole | 18 Years - 45 Years | West-Ward Pharmaceutical | |
| Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant | NCT02894398 | Breast Cancer Hormone Recepto... Human Epidermal... | Palbociclib Letrozole Anastrozole Exemestane Fulvestrant | 18 Years - | iOMEDICO AG | |
| Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | NCT01153672 | Male Breast Can... Recurrent Breas... Stage IV Breast... | vorinostat laboratory biom... biopsy F-18 16 alpha-f... positron emissi... anastrozole letrozole exemestane gene expression... | 18 Years - | University of Washington | |
| Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer | NCT00248170 | Breast Cancer | Letrozole Anastrozole | 33 Years - 96 Years | Novartis | |
| A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer | NCT01216176 | Breast Cancer | Anastrozole AZD0530 (saraca... Placebo | 18 Years - | University of Miami | |
| Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer | NCT00053911 | Breast Cancer | anastrozole cyclophosphamid... docetaxel epirubicin hydr... fluorouracil goserelin aceta... tamoxifen citra... adjuvant therap... | 18 Years - 65 Years | UNICANCER | |
| Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer | NCT01368263 | Estrogen Recept... HER2-negative B... Stage II Breast... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | goserelin aceta... letrozole anastrozole chemotherapy Surgery | 18 Years - | Washington University School of Medicine | |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | NCT05774951 | Breast Cancer, ... | Camizestrant Tamoxifen Anastrozole Letrozole Exemestane | 18 Years - 130 Years | AstraZeneca | |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | NCT06072781 | Low Grade Serou... | avutometinib Defactinib Pegylated lipos... Paclitaxel Topotecan Letrozole Anastrozole | 18 Years - | Verastem, Inc. | |
| A Study of Neoadjuvant Nivolumab + Palbociclib + Anastrozole in Post-Menopausal Women and Men With Primary Breast Cancer | NCT04075604 | Breast Cancer Cancer | Nivolumab Anastrozole Palbociclib | 18 Years - | Bristol-Myers Squibb | |
| Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer Patients Receiving Aromatase Inhibitors | NCT00738998 | Breast Cancer | Questionnaire Phone Calls | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
